Mark Germain Email & Phone Number

New York, Ny, Us

New York, Ny

Jerusalem, Jerusalem, Il

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is developing a pipeline of proprietary "biobetter" nano sized antibodies (NanoAbs) in collaboration with the world recognized research institutions Max Planck and University Medical Center Gottingen. The "biobetter" NanoAbs work through validated targets, eliminating significant upfront cost, time and risk usually associated with new drug development, and leverage unique attributes to create differention for underserved patient populations. www.biondvax.com.

New York, Ny, Us

Managing DirectorAENTIB.com2014 – PresentThe Aentib Group is a global boutique advisory and investment firm offering highly customized solutions to an exclusive set of corporate and private equity clients with the goal of creating high-impact and transformational value on every project.Aentib manages a portfolio of over 30 GP relationships. To date Aentib has designed and implemented over twenty private equity investment programs where there was both a financial and economic impact objectives.In total, Aentib has led the formation of venture capital, private equity and real assets investment programs with over $6 billion under management for banks, SWF's, corporate and state pension fund investors.We also create, fund and build new companies and new venture capital funds through our Aentib Ventures arm.

Boston, Massachusetts, Us

Co-founder/Director and/or Chairman or Co-Chairman of numerous biotech/tech companies (Alexion, Incyte, Neurocrine, Ariad, ChromaDex, Biotechnology General, Pharmos, Peptor, Pluristem, Collexis Holdings and others). Actively involved in formation of companies, recruiting management, financings, initiating and negotiating corporate partnering, technology licensing, M & A, and deciding on and implementing strategic decisions

Boston, Massachusetts, Us

Herron Tech has developed a breakthrough next generation software platform (SOAJS Enterprise) to deliver a total digitization framework that includes microservices management, API lifecycle management, multi-cloud orchestration, resource management, IT Ops automation, all with no coding or development, single pane-of-glass management, end-to-end functional integration and multi-tenant versions and platforms. This open source platform is updated continuously to seamlessly connect with the latest 3rd party platforms and environments, and as such provides durable agility and adaptability, with on premise and SaaS versions that accelerate time-to-value, while reducing costs and ensuring durable integration and inter-operation across the technology stack. Avoid multi-year, expensive and often failed efforts to transform from a legacy environment to a digital organization; no more delays, cost overruns, personnel disruptions and opportunity cost. Bring innovation in-house; reallocate resources away from IT fixes and into launching products and building value.

Los Angeles, California, Us

ChromaDex is an integrated, global nutraceutical company devoted to improving the way people age. Its lead product is TRU NIAGEN (nicotinamide riboside), a natural precursor to NAD+, an essential constituent of robust mitochondrial function, energy production and cell signaling. ChromaDex's key shareholders include Mr. Li Ka-Shing (Chairman Emeritus of CK Hutchison Holdings/Hutchison Whampoa) and his affiliate Horizon Ventures, and Iconiq Capital, the global multi-family office representing, among others, Mark Zuckerberg. Through the relationship with Mr. Li Ka-shing and Horizon Ventures, Niagen is now being offered through A.S. Watson, a member of CK Hutchison Holdings. A.S. Watson is the largest international health and beauty retailer in Asia and Europe with over 13,300 stores in 24 markets.

Haifa, Il

Pluristem is a clinical-stage biotherapy company using placental cells and a unique, proprietary, 3-D technology platform to develop cell therapies for conditions such as inflammation, muscle repair, ischemia, hematological disorders, or exposure to radiation.